Haemonetics (HAE) Q3 2026 earnings review
Plasma Sprints, But Hospital Stumbles Badly
Haemonetics delivered a 'beat and raise' quarter driven entirely by its legacy Plasma business, which surged 20% organically (ex-CSL). However, the narrative is complicated by a sharp deterioration in the Hospital segment—the company's designated growth engine—which flipped to negative organic growth (-0.9%) due to execution failures in Interventional Technologies. While profitability is excellent (Adj. EPS +10%) and cash flow is booming, the thesis drift from 'MedTech Growth' back to 'Plasma Cash Cow' is a significant risk.
🐂 Bull Case
The Plasma business is firing on all cylinders. Excluding the planned CSL exit, organic revenue grew 20.2%, driven by strong collection volumes and technology upgrades. This segment is providing the cash fuel for the rest of the business.
Operational discipline is evident. Adjusted Gross Margin hit 60.2% (+250bps YoY) and Free Cash Flow jumped 151% to $74M. Management raised full-year FCF guidance to $200M-$220M.
🐻 Bear Case
The Hospital segment, intended to be the high-multiple growth driver, has decelerated for four consecutive quarters and turned negative (-0.9%) in Q3. Interventional Technologies collapsed 11.6% due to competitive pressures and execution issues.
Total reported revenue fell 2.7%. While 'Organic Ex-CSL' growth looks good at +7.5%, the reliance on adjustments to tell a positive story is increasing. The divestiture of Whole Blood and loss of CSL revenue creates a smaller, albeit more profitable, top line.
⚖️ Verdict: ⚪
Neutral. The financial discipline and Plasma strength are impressive, justifying the guidance raise. However, the investment case relies on the Hospital segment diversifying the business. Until Interventional Technologies stabilizes, the 'growth' multiple is at risk.
Key Themes
Interventional Technologies Collapse
Reversing. The deterioration in Interventional Technologies (IVT) is accelerating. Revenue fell 11.6% organic in Q3, worsening from a 5% decline in Q2 and a 7% decline in Q1. Management cites 'targeted actions to reestablish momentum,' but the trend line suggests deep structural or competitive issues (Pulsed Field Ablation impact) rather than temporary execution blips.
Profitability Breakout
Accelerating. Adjusted Gross Margin expanded 250 bps YoY to 60.2%, and Adjusted Operating Margin reached 26.3% (+60 bps). This confirms the thesis that shedding lower-margin businesses (Whole Blood) and growing Plasma software/disposables would structurally lift profitability. The raised EPS guidance floor ($4.90 vs $4.80) reflects this efficiency.
Plasma 'Ex-CSL' Outperformance
Accelerating. Plasma organic revenue (excluding CSL) grew 20.2%, an acceleration from 18.6% last quarter. This metric strips out the planned loss of the low-margin CSL contract, revealing that the core plasma business is capturing share and benefiting from strong collection volumes and pricing power.
Blood Center Stabilization
Stable. Despite the massive reported drop (-19.6%) due to the Whole Blood divestiture, the remaining Blood Center business (Apheresis) posted 2.8% organic growth. This legacy segment has transitioned from a drag to a stable cash contributor.
Other KPIs
Accelerating. Up 10.1% YoY, beating expectations. This growth was achieved despite a 2.7% reported revenue decline, showcasing significant margin leverage.
Accelerating. Up 151% YoY. The conversion of income to cash is improving rapidly due to favorable working capital adjustments (lower inventory purchasing) and lower capital expenditures.
Reversing. Down 0.3% reported and down 0.9% organic. This is the first quarter of negative growth for the segment in recent history, marking a stark reversal from the double-digit growth seen in FY25.
Guidance
Accelerating. Raised from prior range of 7-10%. This implies continued strength in Plasma and Blood Center offsetting the weakness in Hospital.
Accelerating. The floor was raised by $0.10 (previous range $4.80-$5.00). Implies ~35% YoY growth at the midpoint vs FY25 ($3.67 YTD vs prior YTD).
Decelerating. Downgraded language. Previous guidance was a range of 4-7% (and 8-11% at start of year). The reduction to '~4%' implies Q4 will remain challenged without a miraculous turnaround.
Accelerating. Raised significantly from $170M - $210M. Management is extracting more cash efficiency from the business than anticipated.
Key Questions
Interventional Technologies Turnaround
IVT organic growth has deteriorated from -5% in Q2 to -11.6% in Q3. What specifically gives management confidence in a turnaround, and is the weakness driven by the structural shift to Pulsed Field Ablation (PFA) impacting your closure or esophageal cooling devices?
Hospital Segment Outlook
With Hospital organic growth turning negative (-0.9%), does this change the long-term algorithm of the company shifting from a Plasma company to a Hospital Growth company?
PerQseal US Launch
The release mentions preparing for a 'US launch of PerQseal Elite.' What is the specific timing and expected contribution in FY27, and does this require significant commercial investment that might weigh on margins?